Comments
Loading...
Ondine Biomedical Analyst Ratings and Price Targets | OTC:OBIMF | Benzinga
Ondine Biomedical Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Ondine Biomedical Corp from these most-recent analyst ratings.
Analyst Ratings for Ondine Biomedical
Data brought to you by Benzinga APIs
FAQ
What is the target price for Ondine Biomedical (OBIMF) stock?
There is no price target for Ondine Biomedical
What is the most recent analyst rating for Ondine Biomedical (OBIMF)?
There is no analyst for Ondine Biomedical
When was the last upgrade for Ondine Biomedical (OBIMF)?
There is no last upgrade for Ondine Biomedical
When was the last downgrade for Ondine Biomedical (OBIMF)?
There is no last downgrade for Ondine Biomedical.
When is the next analyst rating going to be posted or updated for Ondine Biomedical (OBIMF)?
There is no next analyst rating for Ondine Biomedical.
Is the Analyst Rating Ondine Biomedical (OBIMF) correct?
There is no next analyst rating for Ondine Biomedical.
Browse analyst ratings and price targets on all stocks.